Cholesterol as a Master Regulator of Blood Stem Cells
The lifelong production of blood and immune cells, a process known as hematopoiesis, originates from a small population of hematopoietic stem cells (HSCs) residing primarily in the bone marrow. To preserve their function over a lifetime, the vast majority of these HSCs exist in a dormant, or quiescent, state. This is not a passive condition but a highly regulated metabolic state crucial for preventing premature exhaustion and maintaining genomic integrity. While cholesterol is widely recognized for its role in cellular structure and cardiovascular disease, a growing body of evidence reveals it to be a potent and direct regulator of this fundamental hematopoietic process. Elevated levels of low-density lipoprotein (LDL) cholesterol disrupt the protective quiescence of HSCs, initiating a cascade of proliferation, accelerated aging, and lasting epigenetic changes. These alterations reprogram the entire hematopoietic system towards a chronic pro-inflammatory state, providing a compelling molecular basis for the persistent "residual inflammatory risk" observed in patients with cardiovascular disease, even after their cholesterol levels have been therapeutically controlled.
The Disruption of Quiescence by Hypercholesterolemia
A consistent finding across numerous preclinical studies is that hypercholesterolemia acts as a powerful stimulus that drives HSCs out of their protective quiescent state. In mouse models of hypercholesterolemia, there is a significant expansion of the hematopoietic stem and progenitor cell (HSPC) pool in the bone marrow and spleen, coupled with their increased mobilization into the peripheral blood.
This aberrant proliferation is not balanced across all blood lineages. Instead, it is characterized by a distinct skewing towards the myeloid lineage, leading to an overproduction of monocytes and granulocytes—the key cellular players in the inflammatory processes that drive atherosclerosis. This effect appears to be dose-dependent, with high cholesterol directly fueling the production of inflammatory immune cells at their very source. The contrasting roles of lipoproteins are central to this process. Low-density lipoprotein (LDL), or "bad cholesterol," acts as a direct stimulant, promoting HSPC proliferation and their differentiation towards monocytes. Conversely, high-density lipoprotein (HDL), or "good cholesterol," has an opposing, suppressive effect, helping to maintain HSC quiescence and abrogating the pro-inflammatory differentiation induced by LDL. This establishes a dynamic balance where the ratio of LDL to HDL significantly influences the basal state of the hematopoietic system.
Cellular Aging and Epigenetic Memory: The Lasting Scars of High Cholesterol
The chronic replicative stress imposed by high LDL levels comes at a significant cost, inducing a state of accelerated aging within the HSC compartment. Research shows that HSCs from hypercholesterolemic mice accumulate high levels of reactive oxygen species (ROS), leading to a state of chronic oxidant stress. This damages the stem cells, leading to hallmark features of aging, including the shortening of telomeres—the protective caps on chromosomes—and a severely impaired ability to repopulate the hematopoietic system in transplantation assays. The pool of true, long-term HSCs responsible for lifelong blood production shrinks, while the pool of more committed progenitors expands, signifying a loss of "stemness" and an exhaustion of the system's regenerative potential.
Perhaps the most clinically significant finding is that this damage is not easily reversed. HSCs appear to retain an "epigenetic memory" of prior exposure to high cholesterol. Wide-ranging changes to the epigenetic landscape—the physical accessibility of DNA that dictates gene expression—persist even after cholesterol levels are returned to normal. This epigenetic signature is passed down from the stem cell to its progeny, particularly macrophages. Macrophages derived from this "trained" bone marrow exhibit long-term metabolic defects that lock them into a pro-inflammatory state. This provides a powerful molecular explanation for residual inflammatory risk, where a past metabolic insult continues to promote disease long after the initial trigger has been removed.
Molecular Mechanisms of Disruption
The effects of hypercholesterolemia are driven by the activation of specific intracellular signaling pathways that translate the lipid-rich environment into cell fate decisions. The disruption occurs through at least two synergistic mechanisms: a direct growth signal and a potent damage signal.
First, the accumulation of excess intracellular cholesterol activates the PI3K/Akt/mTOR signaling pathway, a master regulator of cell growth and metabolism. Under normal conditions, mTOR activity is low in quiescent HSCs. However, high cholesterol engages cholesterol-sensing mechanisms that activate mTOR, pushing the cell's anabolic machinery into gear and overriding the signals that maintain dormancy.
Second, in parallel with this growth signal, high LDL levels inflict a potent stress signal through oxidative stress. Circulating LDL becomes oxidized (oxLDL), and this modified lipoprotein is taken up by HSCs, leading to the generation of ROS. This, in turn, activates stress-response pathways like p38 MAPK. Activation of this pathway in HSCs disrupts cell cycle regulation, promotes proliferation, and further drives the loss of quiescence. The causal link is confirmed by experiments showing that treatment with the antioxidant N-acetylcysteine (NAC) can reverse these detrimental effects on HSCs in hypercholesterolemic mice, even without lowering cholesterol levels.
Systemic Consequences and the Protective Low-LDL Environment
The consequences of this HSC programming extend far beyond the bone marrow. When "trained" bone marrow is transplanted into healthy mice, the recipients begin to develop adverse metabolic phenotypes, including weight gain, adipose tissue inflammation, and systemic glucose intolerance. This establishes a direct causal link between a history of high cholesterol, persistent epigenetic changes in stem cells, and the development of systemic metabolic disease.
Conversely, a low-LDL environment is fundamentally permissive and supportive of HSC quiescence. It achieves this by removing the chronic pathological stimuli that actively pull HSCs out of their protective state. In a low-LDL milieu, there is reduced oxidative stress, basal mTOR signaling, and a more stable bone marrow niche. Critically, maintaining a lifelong low-LDL environment prevents the initial epigenetic "training" event from ever occurring. Therapeutic interventions like statins contribute to this protective state not only by lowering systemic LDL but also through pleiotropic effects that improve the health of the bone marrow niche itself, enhancing the function of supportive endothelial cells and osteoblasts.
In conclusion, cholesterol is far more than a passive component of atherosclerotic plaques; it is an active and powerful regulator of the hematopoietic system. High LDL cholesterol initiates a damaging cascade in the bone marrow, driving HSCs into a state of oxidative stress, accelerating their aging, and inducing lasting epigenetic changes that program the immune system for a chronic pro-inflammatory response. This paradigm of "hematopoietic memory" underscores the critical importance of early and sustained cholesterol control to preserve the long-term health and integrity of the entire hematopoietic and immune system.
References
- Feng, Y., Schouteden, S., Geenens, R., et al. (2012). Hematopoietic Stem/Progenitor Cell Proliferation and Differentiation Is Differentially Regulated by High-Density and Low-Density Lipoproteins in Mice. PLoS ONE.
- Feng, Y. (2011). LDL and HDL Counteract Hematopoietic Stem/Progenitor Cells in Regulation of Inflammation and Atherosclerosis. Blood (Conference Abstract).
- Ito, K. et al. (2016). Reactive Oxygen Species as Regulators of HSC Quiescence and Aging. Trends in Immunology.
- Oguro, H. (2019). The Roles of Cholesterol and Its Metabolites in Normal and Malignant Hematopoiesis. Frontiers in Endocrinology.
- Purvis, G. S. D., Jiang, J., Hiron, T. K., et al. (2025). Hypercholesterolaemia promotes epigenetic memory in hematopoietic stem cells that persists after lipid lowering and causes systemic immunometabolic dysfunction mediated by macrophage metabolic reprogramming. bioRxiv (Preprint).
- Sajadifar, S. et al. (2016). Hypercholesterolemia Tunes Hematopoietic Stem/Progenitor Cells for Inflammation and Atherosclerosis. International Journal of Molecular Sciences.
- Tie, G., Messina, K. E., Yan, J., Messina, J. A., & Messina, L. M. (2014). Hypercholesterolemia Induces Oxidant Stress That Accelerates the Ageing of Hematopoietic Stem Cells. Journal of the American Heart Association.
- van der Garde, M. et al. (2024). Lipoprotein metabolism mediates hematopoietic stem cell responses under stress. Nature Communications.
- Westerterp, M. et al. (2012). Deficiency of ABCA1 and ABCG1 in HSCs induces lipid raft expansion and HSC proliferation. Cell Stem Cell.

